BRAND_ANALYSIS #SANOFI HEALTH & PHARMA #17 OF 26 IN HEALTH & PHARMA ALIGNED

Sanofi

· Private · Updated 22 Nov 2026 07:19 UTC
#806 of 1208 overall by tension · #17 of 26 in Health & Pharma
10 Aligned
The Balanced
Analysis

Sanofi sits at C=50 and B=60, the profile of a pharmaceutical company that matters to the world far more than it matters to culture. At #806 with a tension score of 10, the scores hold steady, and in this sector that is closer to a virtue than a flaw. Its cultural relevance tends to arrive only in a crisis, which is both the job and the problem.

IN THE NEWS (100 articles this week)
Sanofi's pill becomes first US-approved drug for rare neurological disorder - Reuters
Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact - Fierce Biotech
Facing down Dupixent cliff, Sanofi mulls buyout of Insmed and its blockbuster-to-be Brinsupri: Bloomberg - Fierce Pharma
Cultural Score
50 / 100
Business Score
60 / 100
TENSION▁▁▁▁▁▁▁▁▁▁▁▁▁▁
CULTURAL▄▄▄▄▄▄▄▄▄▄▄▄▃▄
BUSINESS▅▅▅▅▅▄▅▄▅▅▄▄▄▅
Loading...
Wikipedia Momentum 15/40
News Presence 36/35
Search InterestRedistributed to other dimensions
Stock Momentum 0/30
Market Position 0/25
Revenue Growth 0/25
Earnings Health 0/20
Sanofi's tension is 10. Commerce outpacing culture. sociologyofcapitalism.com/brand/sanofi
SHARE ON X
EMBED
<iframe src="https://sociologyofcapitalism.com/embed/sanofi.html" width="320" height="200" frameborder="0"></iframe>